In a prior Technology Evaluation Center (TEC) Assessment (Vol. 16, No. 7; 2001), the Blue Cross and Blue Shield Association Medical Advisory Panel concluded that use of rituximab for patients with intermediate grade or aggressive non-Hodgkins lymphoma (NHL) did not meet the TEC criteria. The earlier Assessments Review of Evidence summarized preliminary results from a randomized controlled trial that compared combination chemotherapy alone to the same combination plus rituximab for patients with diffuse large B-cell lymphoma (the most common type of intermediate/aggressive NHL). At that time, however, these results were available only in meeting abstracts and had not yet been published in a peer-reviewed journal. This randomized trial recently was published in full. Consequently, the objective of this Assessment is to update the Assessment conclusions on the use of rituximab for patients with intermediate or aggressive B-cell NHL.